Number of COVID-19 treatment vaccine trials worldwide by type April 2022

* Definition of listed types:
Treatment: Trials intending to treat (rather than prevent) novel coronavirus (2019-nCoV, COVID-19).
COVID-19 Complication Support: Trials aiming to prevent or treat complications of COVID-19 infection, such as ARDS, Cytokine storm, AKI, Sepsis, etc.
Novel coronavirus (2019-nCoV, COVID-19) pneumonia: Trials that aim to treat or prevent pneumonia due specifically to novel coronavirus (2019-nCoV).
Severe COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms (requiring supplemental oxygen) at screening.
Moderate COVID-19: Trials enrolling subjects with confirmed COVID-19 that have moderate symptoms (respiratory symptoms but supplemental oxygen not needed) at screening.
Mild COVID-19: Trials enrolling subjects with confirmed COVID-19 that have mild upper respiratory symptoms at trial screening.
Novel coronavirus (2019-nCoV, COVID-19) vaccines: Trials with vaccines intended to prevent/treat novel coronavirus (2019-nCoV, COVID-19).
Critical COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms at screening and are in the ICU for critical support. These subjects are likely already on ventilatory support.
Exposure prophylaxis (PEP/PrEP): Trials aiming to prevent COVID-19 infection in subjects at high risk of exposure (ex. Healthcare workers). Includes trials where confirmed exposure has taken place (post-exposure prophylaxis: PEP) as well as trials treating subjects prior to first exposure (pre-exposure prophylaxis: PrEP).
Healthy subjects: Trials enrolling only healthy subjects.
Asymptomatic COVID-19: Trials enrolling subjects with confirmed COVID-19 that are asymptomatic at screening.
Post-COVID Syndrome: Trials aiming to treat Post-COVID Syndrome, including treatment of persistent lung, cardiac or kidney injury after COVID-19 infection.
Unspecified: Trials enrolling patients (not healthy volunteers) but not otherwise specified.